Cargando…
Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms
The advent of immune checkpoint inhibitors (ICIs) has revolutionized the field of oncology, but these are associated with immune related adverse events. One such adverse event, is myocarditis, which has limited the continued immunosuppressive treatment options in patients afflicted by the disease. P...
Autores principales: | Rikhi, Rishi, Karnuta, Jaret, Hussain, Muzna, Collier, Patrick, Funchain, Pauline, Tang, Wai Hong Wilson, Chan, Timothy A., Moudgil, Rohit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381278/ https://www.ncbi.nlm.nih.gov/pubmed/34434981 http://dx.doi.org/10.3389/fcvm.2021.721333 |
Ejemplares similares
-
Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single‐center case series
por: Longinow, Joshua, et al.
Publicado: (2022) -
Better prediction of stroke in atrial fibrillation with incorporation of cancer in CHA(2)DS(2)VASC score: CCHA(2)DS(2)VASC score
por: Bungo, Brandon, et al.
Publicado: (2022) -
Cardiovascular Complications in Major 21(st) Century Viral Epidemics and Pandemics: an Insight into COVID-19
por: Hussain, Muzna, et al.
Publicado: (2021) -
Fulminant Giant Cell Myocarditis vs. Lymphocytic Myocarditis: A Comparison of Their Clinical Characteristics, Treatments, and Outcomes
por: Hu, Yuxiao, et al.
Publicado: (2021) -
Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis
por: Zhang, Xin, et al.
Publicado: (2023)